Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2013-11-06 Share Issue/Capital Cha…
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 221-1 and 223-16 of the AMF General Regulation (French financial regulator). The content is a table showing the total number of shares and voting rights as of a specific date (October 31, 2013). This type of periodic disclosure regarding the total number of shares and voting rights is a standard regulatory filing, but it does not fit the specific definitions for Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or Share Issue/Capital Change (SHA). Since it is a mandatory, periodic regulatory disclosure that doesn't fit a more specific category like DIV or DVA, it falls best under the general Regulatory Filings category (RNS), as it is a routine compliance announcement.
2013-11-06 French
AB Science FR
Regulatory Filings Classification · 95% confidence The document is a press release from AB Science SA, dated November 6, 2013, announcing that the acceleration of its clinical program for Amyotrophic Lateral Sclerosis (ALS) confirms efficacy data obtained in animal models (mice and rats) using the drug masitinib. This content details scientific progress, preclinical results, and provides background on the disease and the drug. It is not a formal regulatory filing like a 10-K, nor is it a short announcement about a report (RPA/RNS). It is a specific update on drug development and research findings, which most closely aligns with an Investor Presentation (IP) or a general regulatory announcement (RNS). Given the detailed scientific nature and focus on development progress, it functions as an Investor Presentation or a specific research update. Since 'Investor Presentation' (IP) covers detailed information for investors on strategy and financials (which often includes R&D progress), and this is a detailed update on R&D, IP is the most appropriate fit over the general 'RNS' fallback. The length (6250 chars) supports it being more than a brief announcement.
2013-11-06 French
AB Science EN
Investor Presentation Classification · 95% confidence The document is a press release dated November 6, 2013, announcing the acceleration of a clinical program for a drug (masitinib) in ALS, supported by positive preclinical (animal) efficacy data. It details scientific rationale, experimental results, and background information on ALS and the drug. This content structure—a formal announcement of scientific/development progress, often following up on previous news (as indicated by 'following the press release from November 4th')—is characteristic of an Investor Presentation (IP) or a general announcement. Since it is a detailed update on development progress and scientific findings aimed at investors, Investor Presentation (IP) is the most fitting category, as it conveys strategic and scientific information beyond a simple Earnings Release (ER) or a brief Regulatory Filing (RNS). It is not a formal regulatory report like a 10-K or IR.
2013-11-06 English
AB Science EN
Regulatory Filings Classification · 95% confidence The document is a press release from AB Science announcing the initiation of a clinical development program (Phase 3 study) for their drug 'masitinib' in treating ALS. It provides details on the clinical trial design, the disease background, and the company's research focus. It does not contain financial statements, dividend information, or regulatory filings, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations and clinical progress that does not fit into specific financial categories, it is classified as a Regulatory Filing (RNS). Q4 2013
2013-11-04 English
AB Science FR
Legal Proceedings Report Classification · 99% confidence The document is a press release dated November 4, 2013, from AB Science SA, announcing clinical trial updates regarding the drug masitinib for Amyotrophic Lateral Sclerosis (ALS). It details patient recruitment numbers, phase progression (Phase 2 transforming into Phase 3), and provides scientific context and company background. This type of announcement, focusing on clinical trial progress and scientific updates rather than formal financial results (like 10-K or ER) or management changes, fits best under a general category for corporate or scientific updates. Since it is not a formal financial report, a proxy statement, or a transcript, and it is not explicitly a Director's Dealing or Dividend notice, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides. Given the format is a press release detailing R&D progress, RNS (Regulatory News Service/General Regulatory Announcement) is the most appropriate fallback for non-standard, material corporate news that isn't covered by the other specific codes. It is not an Earnings Release (ER) or Interim Report (IR) as it focuses on clinical trials, not financial performance metrics for a period.
2013-11-04 French
AB Science information trimestrielle T3 2013
Earnings Release Classification · 99% confidence The document is explicitly titled "Information trimestrielle – Troisième trimestre 2013" (Quarterly Information – Third Quarter 2013) and provides detailed financial figures (revenue, cash position) for the nine-month period ending September 30, 2013. This structure—a comprehensive financial report covering a period shorter than a full year—aligns perfectly with the definition of an Interim/Quarterly Report. It is not merely an announcement of a report (RPA) because it contains the substantive financial data itself. Therefore, the appropriate classification is IR. Q3 2013
2013-10-15 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.